Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Aug 25;48(17):5551-60.
doi: 10.1021/jm0501228.

Defunctionalized lobeline analogues: structure-activity of novel ligands for the vesicular monoamine transporter

Affiliations

Defunctionalized lobeline analogues: structure-activity of novel ligands for the vesicular monoamine transporter

Guangrong Zheng et al. J Med Chem. .

Abstract

(-)-Lobeline (2R,6S,10S), an antagonist at nicotinic acetylcholine receptors (nAChRs), inhibits the neurochemical and behavioral effects of methamphetamine and inhibits dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) function. VMAT2 is a target for the development of treatments for methamphetamine abuse. Structural modification of lobeline affords the defunctionalized analogues meso-transdiene (MTD) and lobelane, which have high potency and selectivity for VMAT2. To establish the structure-activity relationships within this novel class of VMAT2 ligands, specific stereochemical forms of MTD, lobelane, and other structurally related analogues have been synthesized. These compounds have been evaluated for inhibition of [(3)H]nicotine ([(3)H]NIC) binding (alpha4beta2 nAChR), [(3)H]methyllycaconitine ([(3)H]MLA) binding (alpha7 nAChR), and [(3)H]dihydrotetrabenazine ([(3)H]DTBZ) binding (VMAT2). Generally, all of these analogues had lower affinities at alpha4beta2 and alpha7 nAChRs compared to lobeline, thereby increasing selectivity for VMAT2. The following structural modifications resulted in only modest changes in affinity for VMAT2, affording analogues that were less potent than the lead compound, lobelane: (1) altering the stereochemistry at the C-2 and C-6 positions of the piperidino ring, (2) varying unsaturation in the piperidino C-2 and C-6 substituents, (3) introducing unsaturation into the piperidine ring, (4) ring-opening or eliminating the piperidine ring, and (5) removing the piperidino N-methyl group. Furthermore, incorporating a quaternary ammonium group into defunctionalized lobeline molecules in the cis-series resulted in significant loss of affinity for VMAT2, whereas only a modest change in affinity was obtained in the trans-series. The most potent (K(i) = 630 nM) and VMAT2-selective compound evaluated was the N-methyl-2,6-cis-bis(naphthaleneethyl)piperidine analogue (1-NAP-lobelane), in which the phenyl groups of lobelane were replaced with 1-naphthyl moieties. Thus, initial structure-activity relationship studies reveal that the most promising structural changes to the lobeline molecule that lead to enhancement of VMAT2 affinity and selectivity are defunctionalization, affording lobelane and MTD, and replacement of the phenyl rings of lobelane with other aromatic moieties that have a pi-extended structure.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Figure 2
Figure 2
Scheme 1<sup>a</sup>
Scheme 1a
a Reagents and conditions: (a) K2CO3, MeOH; (b) NaBH4, EtOH, rt; (c) 85% H3PO4, 60 °C; (d) H2, 10% Pd/C, MeOH, 45 psi; (e) Zn/Hg, HCl (5%), reflux; (f) CrO3, H2SO4, acetone, 0 °C; (g) H2, 10% Pd/C, 10% HOAc/MeOH, 45 psi.
Scheme 2<sup>a</sup>
Scheme 2a
a Reagents and conditions: (a) H2, 10% Pd/C, MeOH, 45 psi; (b) p-C6H4SO3CH3, 170–180 °C; (c) NaBH4, EtOH, 0 °C; (d) H2, PtO2, HOAc, 45 psi.
Scheme 3<sup>a</sup>
Scheme 3a
a Reagents and conditions: (a) NaBH4, EtOH, rt; (b) 85% H3PO4, 60 °C.
Scheme 4<sup>a</sup>
Scheme 4a
a Reagents and conditions: (a) 1- or 2-naphthaldehyde, Ac2O, reflux; (b) H2, PtO2, 10% HOAc/MeOH, 45 psi; (c) NaCNBH3, (CH2O)n, MeOH, rt.

Similar articles

Cited by

References

    1. Wise RA, Bozarth MA. A psychomotor stimulant theory of addiction. Psychol Rev. 1987;94:469–492. - PubMed
    1. Koob GF. Neural mechanisms of drug reinforcement. Ann NY Acad Sci. 1992;654:171–191. - PubMed
    1. Fleckenstein AE, Hanson GR. Impact of psychostimulants on vesicular monoamine transporter function. Eur J Pharmacol. 2003;479:283–289. - PubMed
    1. Brown JM, Hanson GR, Fleckenstein AE. Methamphetamine rapidly decrease vesicular dopamine uptake. J Neurochem. 2000;74:2221–2223. - PubMed
    1. Brown JM, Hanson GR, Fleckenstein AE. Regulation of the vesicular monoamine transporter-2: A novel mechanism for cocaine and other psychostimulants. J Pharmacol Exp Ther. 2001;296:762–767. - PubMed

Publication types